GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease.

Keyphrases

• Chemokine Receptor 100%
• Crohn's Disease 100%
• CCR9 100%
• Small Molecule Antagonist 100%
• T Cells 50%
• B Cells 50%
• Celiac Disease 50%
• Orally Bioavailable 25%
• CC Chemokine Receptor 25%
• Phase II Trial 25%
• Moderate to Severe 25%
• Immune Function 25%
• Selective Antagonist 25%
• Inflammatory Bowel Disease 25%
• Inflammation 25%
• Potential Treatments 25%
• Anatomical Location 25%
• Leukocyte Trafficking 25%
• Cell Entry 25%
• GlaxoSmithKline 25%

Immunology and Microbiology

• Chemokine Receptor 100%
• Crohn's Disease 100%
• CCR9 100%
• T Cell 50%
• B Cell 50%
• Coeliac Disease 50%
• CC Chemokine Receptors 25%
• Lymphocyte 25%
• Immunity 25%
• Inflammatory Bowel Disease 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Crohn's Disease 100%
• Glycogen Synthase Kinase 100%
• Chemokine Receptor CCR9 100%
• Coeliac Disease 40%
• Inflammation 20%
• Phase II Trials 20%
• Inflammatory Bowel Disease 20%
• Beta Chemokine 20%